Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)

• Published in: Cancer research (Chicago, Ill.) Vol. 82; no. 4_Supplement; pp. P5 - P5-16-01
• Main Authors: Loibl, Sibylle, Tolaney, Sara M., Punie, Kevin, Oliveira, Mafalda, Rugo, Hope S., Bardia, Aditya, Hurvitz, Sara A., Brufsky, Adam, Kalinsky, Kevin M, Cortes, Javier, O’Shaughnessy, Joyce, Carey, Lisa A., Gianni, Luca, Diéras, Véronique, Shi, Ling, Gharaibeh, Mahdi, Preger, Luciana, Moore, Lee, Phan, See, Piccart, Martine
• Format: Journal Article
• Language: English
• Published: 15.02.2022

Abstract Background: In ASCENT, patients with mTNBC refractory to or relapsing after ≥2 prior chemotherapies (at least one in the metastatic setting) were randomized 1:1 to receive sacituzumab govitecan (SG) or single-agent treatment of physician’s choice (TPC) (capecitabine, eribulin, vinorelbine,...